Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ACCEL-HYOSCINE - Health Canada Drug Approval Details

Approvals/Health Canada/ACCEL-HYOSCINE

Authorized

STANDARD

ACCEL-HYOSCINE

accel pharma inc🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 6e4f693dc9552d08
Company: accel pharma inc
Type: Standard

Approval Details

Approval Id: 6e4f693dc9552d08
Drug Approval Canada Name: ACCEL-HYOSCINE
Product Name: ACCEL-HYOSCINE
Status: Marketed
Status Date: 2021-08-19
Original Market Date: 2021-08-19
Din: 02512335
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Oral
Schedule: Ethical
Ahfs: 12:08.08
Atc Original: A03BB01 BUTYLSCOPOLAMINE
Atc Name: a 03 bb 01
Aig Number: 0104703001
Company Name: accel pharma inc
Company Address: 119 Labrosse Ave, Pointe Claire, Quebec, Canada, H9R 1A3

Active Ingredients

HYOSCINE BUTYLBROMIDE

10 MG

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

6e4f693dc9552d08

Type

Standard

Back to Health Canada Approvals